• In early April 2026, Eli Lilly and Company received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 pill for adults with obesity or overweight with weight-related medical problems, with U.S. availability beginning via LillyDirect and retail pharmacies from April 6.
• Foundayo’s ability to be taken at any time without food or water restrictions, alongside trial data showing meaningful weight loss and cardiometabolic improvements, positions it as a differentiated oral alternative to injectable obesity therapies and intensifies its head-to-head competition with Novo Nordisk’s Wegovy pill.
• We’ll now examine how Foundayo’s approval as an anytime, needle-free GLP-1 pill could reshape Eli Lilly’s GLP-1-led investment narrative.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Eli Lilly Investment Narrative Recap

To own Eli Lilly today, you have to believe its GLP‑1 franchise can justify a premium valuation while the company gradually reduces its reliance on a handful of obesity and diabetes blockbusters. Foundayo’s approval strengthens the near term obesity catalyst by adding a needle free, scalable GLP‑1 option, but it also heightens the key risk around pricing pressure and payer pushback as obesity treatments move deeper into mainstream reimbursement debates.

Among Lilly’s recent announcements, the TOGETHER‑PsA Phase 3b data linking Zepbound with Taltz is especially relevant. It shows Lilly trying to extend incretin use into complex comorbid populations, which could reinforce the GLP‑1 narrative around cardiometabolic benefit if future labels and guidelines follow, but also concentrates even more expectation and scrutiny on this drug class as a single engine for growth.

Yet behind the enthusiasm for Foundayo, investors should be aware of how mounting pricing pressure and payer decisions could eventually reshape...

Eli Lilly's narrative projects $89.1 billion revenue and $34.2 billion earnings by 2028.

Uncover how Eli Lilly's forecasts yield a $1211 fair value, a 29% upside to its current price.

Exploring Other Perspectives

The most bullish analysts were already assuming Lilly could reach about US$123.4 billion in revenue and US$49.4 billion in earnings by 2029, so if you buy into that more optimistic view you are also accepting much bigger exposure to the same incretin pricing and access risks those forecasts depend on.

Explore 28 other fair value estimates on Eli Lilly - why the stock might be worth 6% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Eli Lilly research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.